BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37850501)

  • 1. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
    Zhan XK; Liu XK; Zhang S; Chen H
    Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
    Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
    Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
    Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
    Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
    Front Immunol; 2022; 13():992614. PubMed ID: 36119089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis.
    Provera A; Ramavath NN; Gadipudi LL; Gigliotti CL; Boggio E; Vecchio C; Stoppa I; Rolla R; Boldorini R; Pirisi M; Smirne C; Albano E; Dianzani U; Sutti S
    Front Immunol; 2023; 14():1290391. PubMed ID: 38077334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of polymorphisms in the ICOS and ICOSL genes with the pathogenesis of autoimmune thyroid diseases.
    Yoshie N; Watanabe M; Inoue N; Kawaguchi H; Hidaka Y; Iwatani Y
    Endocr J; 2016; 63(1):61-8. PubMed ID: 26560438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.
    Kunishige T; Taniguchi H; Terada M; Akiba H; Yagita H; Abe R; Hori J
    Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6815-6823. PubMed ID: 28002569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
    Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
    Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High expression of ICOS on CD4
    Chen X; Wang F; Cong X; Shen Q; Chen L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Dec; 36(12):1102-1108. PubMed ID: 33325362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
    Le KS; Thibult ML; Just-Landi S; Pastor S; Gondois-Rey F; Granjeaud S; Broussais F; Bouabdallah R; Colisson R; Caux C; Ménétrier-Caux C; Leroux D; Xerri L; Olive D
    Cancer Res; 2016 Aug; 76(16):4648-60. PubMed ID: 27246829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
    Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
    Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
    Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
    Front Immunol; 2021; 12():786680. PubMed ID: 34925367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo.
    Stoppa I; Gigliotti CL; Clemente N; Pantham D; Dianzani C; Monge C; Puricelli C; Rolla R; Sutti S; Renò F; Boldorini R; Boggio E; Dianzani U
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
    Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
    Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
    Front Immunol; 2018; 9():2227. PubMed ID: 30319662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
    Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
    BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
    Solinas C; Gu-Trantien C; Willard-Gallo K
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
    Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
    Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.
    Zhou A; Shi C; Fan Y; Zheng Y; Wang J; Liu Z; Xie H; Liu J; Jiao Q
    Front Immunol; 2023; 14():1171308. PubMed ID: 37325657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.
    Chattopadhyay K; Bhatia S; Fiser A; Almo SC; Nathenson SG
    J Immunol; 2006 Sep; 177(6):3920-9. PubMed ID: 16951355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.